Adult doses of dolutegravir can be used by children weighing 20 kg or more
HIV programmes in Africa need new models of care for people’s first six months on treatment
No increased risk of diabetes with integrase inhibitors in people starting HIV treatment
Trans and cis women and men all have similar levels of PrEP drugs in blood, directly observed dosing study finds
Two different cases of PrEP failure despite high adherence underline that such events are rare, but should not be ignored
High prevalence of underlying health conditions explains increased COVID-19 mortality seen in people with HIV in US study
Fewer antiretroviral drug interactions due to use of integrase inhibitors, says Swiss study
Two UK studies find that HIV infection may be a risk factor for dying from COVID-19
“Unprecedented” case of transmission of four-class resistant HIV virus reported in France
